Elisa R Port, MD
- PROFESSOR | Surgery
- Surgical Oncology
- Breast Cancer - Surgery
- Hospital Affiliations
- Mount Sinai Brooklyn
- The Mount Sinai Hospital
- Mount Sinai Beth Israel
- Mount Sinai Queens
- Mount Sinai Morningside and Mount Sinai West
- New York Eye and Ear Infirmary of Mount Sinai
I am a surgeon who specializes in the care and treatment of patients with breast cancer, and those at increased risk for breast cancer. I have extensive experience with sentinel lymph node biopsy, nipple sparing mastectomy, and the newest techniques in breast cancer surgery for both invasive breast cancer and DCIS.
I am the author of a variety of publications on the role of sentinel lymph node biopsy in breast cancer, the role of MRI in patients at high risk for breast cancer, and I have received a Komen Foundation Grant investigating the role of PET scanning in breast cancer. I recently completed an NCI funded clinical trial investigating the effects of the COX2 inhibitor, Celebrex, on breast cancer tissue.
I am a member of many professional organizations including the Society of Surgical Oncology, the American Society of Breast Diseases, the American Society of Breast Surgeons, and the American College of Surgeons Oncology Group.
In the News:
- Dr. Port explains a one-time treatment for early breast cancer in KSAT ABC and WQAD-TV.
- Read in the New York Post how Dr. Port is credited for saving lives through her hard work as the Chief of Breast Surgery at Mount Sinai.
American Board of Surgery
- Breast Cancer
- Breast Surgery
BA, Dartmouth College
MD, Mount Sinai School of Medicine
Residency, General Surgery
Cedars-Sinai Medical Center
Residency, General Surgery
Long Island Jewish Medical Center
American College of Surgeons
Honors in Surgery
Mount Sinai School of Medicine
Third Honor Group
Applications of sentinel lymph node biopsy for breast cancer
NCI Sponsored Trial
Investigating COX-2 inhibition and aromatase activity in breast cancer
Susan G. Komen Foundation Research Grant
Study of the role of Positron Emission Tomography (PET) scanning in the pre-operative management of patients with breast cancer
MRI in women at increased risk for breast cancer
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Port during 2019 and/or 2020. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- angiocrine biosciences
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.